Potential diagnostic value of methylation profile in pleural fluid and serum from cancer patients with pleural effusion
Open Access
Abstract
BACKGROUND.: The objective of this study was to investigate the diagnostic value of methylation profiles for discrimination between malignant and benign pleural effusions. A secondary objective was to examine the concordance of methylation in samples of serum and pleural fluid.METHODS.: The authors used methylation‐specific polymerase chain reaction (MSP) analysis to examine the promoter methylation status of 4 genes in patients with pleural effusion: death‐associated protein kinase (DAPK), Ras association domain family 1A (RASSF1A), retinoic acid receptor β (RARβ), and p16/INK4a. Pleural effusions were collected from 87 patients who had their diagnoses confirmed on cytologic and/or histologic examinations and clinical evolution. Pleural effusions were classified as malignant (n = 53 patients) or benign (n = 34 patients).RESULTS.: Methylation was detected in serum from 45.3% of patients with malignant pleural effusions and from 0% of patients with benign pleural effusions, and it was detected in pleural fluid samples from 58.5% of patients with malignant pleural effusions and from 0% of patients with benign pleural effusions (P = .001). The sensitivity of MSP was greater than that of cytologic examination alone (39.1%; P = .001). When MSP was used together with cytologic examination, sensitivity increased to 69.8% (P = .001).CONCLUSIONS.: Cell‐free methylated DNA in pleural fluid can be detected in patients with neoplastic malignancy in a single extraction by thoracocentesis. Adequate management of the extracted pleural fluid can provide a rapid and reliable diagnosis in patients with pleural effusions who have suspected malignancy. MSP, used together with cytologic examination, may obviate the need for other invasive diagnostic tests. Cancer 2006. © 2006 American Cancer Society.Keywords
This publication has 24 references indexed in Scilit:
- 14-3-3σ Methylation in Pretreatment Serum Circulating DNA of Cisplatin-Plus-Gemcitabine-Treated Advanced Non–Small-Cell Lung Cancer Patients Predicts Survival: The Spanish Lung Cancer GroupJournal of Clinical Oncology, 2005
- Aberrant Promoter Hypermethylation of Multiple Genes in Gallbladder Carcinoma and Chronic CholecystitisClinical Cancer Research, 2004
- Detection of Promoter Hypermethylation of Multiple Genes in the Tumor and Bronchoalveolar Lavage of Patients with Lung CancerClinical Cancer Research, 2004
- Quantitative Plasma Hypermethylated DNA Markers of Undifferentiated Nasopharyngeal CarcinomaClinical Cancer Research, 2004
- Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patientsCancer Letters, 2003
- Expression of various genes is controlled by DNA methylation during mammalian developmentJournal of Cellular Biochemistry, 2003
- DNA methylation analysis: a powerful new tool for lung cancer diagnosisOncogene, 2002
- The DNA methylation paradoxTrends in Genetics, 1999
- Cancer Cell CyclesScience, 1996
- CEA, CA 15-3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusionsEuropean Respiratory Journal, 1996